The English University of Oxford has initiated this clinical trial to test the efficacy in nines from 6 to 17 years of the antiviral vaccine that it has developed with the pharmaceutical AstraZeneca, in that it considers the first tests in the world in minor cases. .
In a statement, investigators explain that the tests to determine the security and immunity of the children to the technically known vaccine as ChAdOx1 nCoV-19 are being developed in the centers of Oxford, London, Southampton and Bristol.
For these purposes, 300 volunteers will be recruited, of which 240 will receive the Oxford / AstraZeneca vaccine and the rest is a control vaccine against meningitis.
According to the University of Oxford, there are first-class students with a few children from a vacancy against the covid, you can only now have rehearsals with 16 and 17-year-olds, as they are currently authorized for public use .
Oxford’s investigator and expert on infant infections and immunization, Andrew Pollard, said that although some nests appear to be less affected by coronavirus and it is not likely that pregnancy is confirmed, “it is important to establish immunity and immune response” the vaccine, which some minors can “benefit from being vaccinated”.
The Oxford / AstraZeneca vaccine is, together with the Moderna y Pfizer / BioNTech, one of the three currently being administered in the United Kingdom, which aims to increase the proximity of the target population to the four groups most vulnerable of the company, one 15 million people.
In pre-adult studies, it has been demonstrated that the British preparation, which is also distributed in the European Union and is offered at the expense of the countries in passing, is effective at 63%, inoculated in two doses separated by also in 12 weeks, and is currently investing in its efficient new variants of the virus.